Revision 34 for 'Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL)'

All Revisions - View changeset


Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) is a systemic genetic disorder affecting the cerebral small vessels, spine and hair follicles. It is inherited in an autosomal recessive pathway and should not be confused with its autosomal dominant counterpart CADASIL - autosomal recessive inherited diseases are usually more severe than autosomal dominant genetic disorders and CARASIL is no exception to this rule.

CARASIL is (after CADASIL) the second known genetic form of ischemic CNS disease caused by non-hypertensive microangiopathy in which the causative gene defect has been identified.


CARASIL is a very rare disease with roughly 50 cases reported, until recently not outside Asia 1. However a recent study has documented it in an European family 2.

The true prevalence is unknown and CARASIL is probably under recognized, since no founder haplotype has been identified 1 and the recently encountered European disease carriers support the theory of a wider distribution 2,4.


Gross pathology

Shows cerebral arteriosclerotic changes, most intense in white matter and basal ganglia.


Intense arteriosclerosis is seen predominantly in the small penetrating arteries. Aids in differentiation from other entities are the lack of amyloid deposition and absence of the granular appearance characteristics of CADASIL.

Extraneural changes are less severe and although they include the cutis, skin biopsies are not helpful in establishing the diagnosis.


Mutations in HTRA1 gene on chromosome 10q (10q25.3-q26.2) are responsible for CARASIL. It codes for the ubiquitary HTRA1 enzyme, which regulates signaling by proteins in the transforming growth factor-beta (TGF-β) family, which again is essential for multiple critical cell functions including angiogenesis. The pivotal role of TGF-β in CARASIL is hypothesized, but not totally clarified.

Clinical presentation

Typically patients present in their young ages (twenties and thirties) with

  • premature alopecia (most common initial symptom)
  • relapsing ischemic stroke-like episodes with gradually progressive vascular dementia
  • not infrequently symptomatic epilepsy (secondary to infarctions)
  • relapsing severe low back pain and deforming spondylosis (present in roughly 80% of patients, very early onset noteworthy)

Radiographic features

CNS manifestations
Musculoskeletal manifestations

Changes may be appreciated by plain radiograph, CT or MRI, and are those of:

  • deforming spondylosis with or without intervertebral space narrowing, located in the cervical and/or thoracolumbar spine
    • typical location upper lumbar regions (which is in some contradiction to the sporadic spondylosis) 
    • kyphosis
  • elbow or knee osteoarthritis 

Treatment and prognosis

As there are no causative treatment options, treatment focuses on the prevention of ischemic strokes. Interestingly, treatment with known antiplatelet agents and anticoagulant lacks evidence. 

Another goal of management is to prevent the onset of dementia symptoms. Genetic counseling is also an important part of primary care.

History and etymology

It was first described by S Nemoto, a Japanese physician, in 1960 where it was initially described as part of the Binswanger spectrum 5,6. Nemoto went on to publish a seminal case series with S Maeda et al. in 1976 7. The disease is sometimes known as Nemoto disease or Maeda syndrome in recognition of their contributions.

Differential diagnosis

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.